Treatment with both Linsitinib and JSH‐23 exhibited increased efficacy of Linsitinib in Linsitinib‐resistant cells, indicating that targeting on both IGF‐1R and NF‐κB may generate a promising therapeutic effect on ESCC. Here, IGF1R is linked to esophageal squamous cell carcinoma.